CoChat

Coadministration of Glucagon-Like Peptide-1 During Glucagon Infusion in Humans Results in Increased Energy Expenditure and Amelioration of Hyperglycemia

Open access

The DOI matches its Crossref record; the references it cites are not checked yet.

Abstract

Glucagon and glucagon-like peptide (GLP)-1 are the primary products of proglucagon processing from the pancreas and gut, respectively. Giving dual agonists with glucagon and GLP-1 activity to diabetic, obese mice causes enhanced weight loss and improves glucose tolerance by reduction of food intake and by increase in energy expenditure (EE). We aimed to observe the effect of a combination of glucagon and GLP-1 on resting EE and glycemia in healthy human volunteers. In a randomized, double-blinded crossover study, 10 overweight or obese volunteers without diabetes received placebo infusion, GLP-1 alone, glucagon alone, and GLP-1 plus glucagon simultaneously. Resting EE—measured using indirect calorimetry—was not affected by GLP-1 infusion but rose significantly with glucagon alone and to a similar degree with glucagon and GLP-1 together. Glucagon infusion was accompanied by a rise in plasma glucose levels, but addition of GLP-1 to glucagon rapidly reduced this excursion, due to a synergistic insulinotropic effect. The data indicate that drugs with glucagon and GLP-1 agonist activity may represent a useful treatment for type 2 diabetes and obesity. Long-term studies are required to demonstrate that this combination will reduce weight and improve glycemia in patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/db12-0797

Cites

Statistics

Figures

FIG. 1. Plasma GLP-1 (A) and glucagon (B) levels after hormone infusion. Mean ± SEM plasma venous levels plotted. Duration of infusion from 45 to 90 min denoted by gray bar.
FIG. 1. Plasma GLP-1 (A) and glucagon (B) levels after hormone infusion. Mean ± SEM plasma venous levels plotted. Duration of infusion from 45 to 90 min denoted by gray bar.CC BY-NC-ND · PubMed Central
FIG. 2. Effects of glucagon, GLP-1, and GLP-1 plus glucagon infusion on glucose (A and B) and insulin (C and D) levels. A and C: Mean ± SEM venous plasma glucose and serum insulin levels plotted. Duration of infusion from 45 to 90 min denoted by gray bar. *P < 0.05, ***P < 0.001, ****P < 0.0001 compared with placebo. B: Area under the glucose curve ±SEM plotted. Significantly different area under the curve values are indicated as follows: ##P < 0.01, ###P < 0.001 compared with placebo; †P < 0.05 compared with glucagon. D: Area under the insulin curve ±SEM plotted. Significantly different area under the curve values are indicated as follows: $P < 0.05, $$$P < 0.001 compared with placebo; %%P < 0.01 compared with glucagon.
FIG. 2. Effects of glucagon, GLP-1, and GLP-1 plus glucagon infusion on glucose (A and B) and insulin (C and D) levels. A and C: Mean ± SEM venous plasma glucose and serum insulin levels plotted. Duration of infusion from 45 to 90 min denoted by gray bar. *P < 0.05, ***P < 0.001, ****P < 0.0001 compared with placebo. B: Area under the glucose curve ±SEM plotted. Significantly different area under the curve values are indicated as follows: ##P < 0.01, ###P < 0.001 compared with placebo; †P < 0.05 compared with glucagon. D: Area under the insulin curve ±SEM plotted. Significantly different area under the curve values are indicated as follows: $P < 0.05, $$$P < 0.001 compared with placebo; %%P < 0.01 compared with glucagon.CC BY-NC-ND · PubMed Central
FIG. 3. Effects of glucagon, GLP-1, and GLP-1 plus glucagon infusion on NEFA levels. Means ± SEM plotted for NEFA levels during the baseline phase (30 min) and at the end of the infusion phase (90 min). ***P < 0.001 for difference between baseline and infusion phase values.
FIG. 3. Effects of glucagon, GLP-1, and GLP-1 plus glucagon infusion on NEFA levels. Means ± SEM plotted for NEFA levels during the baseline phase (30 min) and at the end of the infusion phase (90 min). ***P < 0.001 for difference between baseline and infusion phase values.CC BY-NC-ND · PubMed Central
FIG. 4. Effects of infusions on EE. The mean changes in each parameter (±95% CI) between baseline and infusion phases are plotted. Baseline resting EEs were as follows: 1,487 ± 70.9 kcal/day (placebo), 1,487 ± 65.9 kcal/day (GLP-1), 1,469 ± 66.0 kcal/day (glucagon), and 1,485 ± 67.4 kcal/day (GLP-1 plus glucagon); they were not significantly different (P = 0.7253, one-way repeated-measures ANOVA). Baseline RQ values for all arms were 0.822 ± 0.018 (placebo), 0.857 ± 0.018 (GLP-1), 0.851 ± 0.020 (glucagon), and 0.834 ± 0.022 (GLP-1 plus glucagon), and these were not significantly different (P = 0.5138, one-way repeated-measures ANOVA). A linear mixed-model analysis of repeated observations within subjects was used to compare these differences for each arm. P values for the observed differences in each parameter are indicated at the top of each graph. A: ΔResting EE (expressed as kilocalories per day). B: ΔRQ (Vco2/Vo2). C: ΔCarbohydrate (CHO) oxidation (ox) rates (grams per minute). D: ΔFat oxidation rates (grams per minute).
FIG. 4. Effects of infusions on EE. The mean changes in each parameter (±95% CI) between baseline and infusion phases are plotted. Baseline resting EEs were as follows: 1,487 ± 70.9 kcal/day (placebo), 1,487 ± 65.9 kcal/day (GLP-1), 1,469 ± 66.0 kcal/day (glucagon), and 1,485 ± 67.4 kcal/day (GLP-1 plus glucagon); they were not significantly different (P = 0.7253, one-way repeated-measures ANOVA). Baseline RQ values for all arms were 0.822 ± 0.018 (placebo), 0.857 ± 0.018 (GLP-1), 0.851 ± 0.020 (glucagon), and 0.834 ± 0.022 (GLP-1 plus glucagon), and these were not significantly different (P = 0.5138, one-way repeated-measures ANOVA). A linear mixed-model analysis of repeated observations within subjects was used to compare these differences for each arm. P values for the observed differences in each parameter are indicated at the top of each graph. A: ΔResting EE (expressed as kilocalories per day). B: ΔRQ (Vco2/Vo2). C: ΔCarbohydrate (CHO) oxidation (ox) rates (grams per minute). D: ΔFat oxidation rates (grams per minute).CC BY-NC-ND · PubMed Central
FIG. 5. Effects of infusions on total (A) and acylated (B) ghrelin levels (picograms per milliliter). Means ± SEM plotted for the baseline phase and at the end of the infusion phase. *P < 0.05, **P < 0.01.
FIG. 5. Effects of infusions on total (A) and acylated (B) ghrelin levels (picograms per milliliter). Means ± SEM plotted for the baseline phase and at the end of the infusion phase. *P < 0.05, **P < 0.01.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

The citation lists are queued

They are fetched later and appear here then.

References 44 · Cited by 258

Metadata

Authors
Tan, T. M., Field, B. C. T., McCullough, K. A., Troke, R. C., Chambers, E. S., Salem, V., Gonzalez Maffe, J., Baynes, K. C. R., De Silva, A., Viardot, A., Alsafi, A., Frost, G. S., Ghatei, M. A., & Bloom, S. R.
Affiliations
  • Imperial College London (GB)
  • Imperial Clinical Trials Unit, Imperial College London, London, U.K.
  • Section of Investigative Medicine, Imperial College London, London, U.K.
Corresponding author
Bloom, Stephen R.
Venue
Diabetes
Published
2013-03-14
Volume
62
Issue
4
Pages
1131-1138
ISSN
  • 0012-1797 (ISSN-L)
  • 1939-327X
OpenAlex
W2148623180
Cited by
258
References
44
Citations by year
2026: 13 · 2025: 19 · 2024: 30 · 2023: 28 · 2022: 20 · 2021: 18 · 2020: 15 · 2019: 17 · 2018: 25 · 2017: 16 · 2016: 13 · 2015: 20 · 2014: 13 · 2013: 11
FWCI
11.29
Type
journal article
Language
en
Open access
Locations
  • Diabetes (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
  • Imperial College Healthcare Charity
  • National Institute for Health and Care Research (FP7-HEALTH-2009-241592, NF-SI-0508-10112)
  • Imperial College London
  • Imperial College Healthcare NHS Trust
  • Directorate for Biological Sciences
  • Medical Research Council (FP7-HEALTH-2009-241592)
  • Biotechnology and Biological Sciences Research Council (FP7-HEALTH-2009-241592 EuroCHIP, FP7-HEALTH-2009-241592)
  • NIHR Imperial Biomedical Research Centre
  • FP7 Health (2009-241592 EuroCHIP)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
Keywords
glucagon-like peptide-1, glucagon, co-administration, energy expenditure, hyperglycemia, insulinotropic effect, proglucagon, obesity, type 2 diabetes, glucose tolerance, weight loss
MeSH terms
Adult, Calorimetry, Indirect, Double-Blind Method, Energy Metabolism, Female, Glucagon, Humans, Hyperglycemia, Infusions, Intravenous, Male, Middle Aged, Cross-Over Studies, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Coadministration of Glucagon-Like Peptide-1 During Glucagon Infusion in Humans Results in Increased Energy Expenditure and Amelioration of Hyperglycemia. https://app.cochat.ai/papers/10.2337/db12-0797
The paper
Tan, T. M., Field, B. C. T., McCullough, K. A., Troke, R. C., Chambers, E. S., Salem, V., Gonzalez Maffe, J., Baynes, K. C. R., De Silva, A., Viardot, A., Alsafi, A., Frost, G. S., Ghatei, M. A., & Bloom, S. R. (2013). Coadministration of Glucagon-Like Peptide-1 During Glucagon Infusion in Humans Results in Increased Energy Expenditure and Amelioration of Hyperglycemia. Diabetes. https://doi.org/10.2337/db12-0797

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.